Phase Ib ACE-CL-003: Acalabrutinib Combined With Venetoclax and Obinutuzumab or Rituximab in Treatment-Naive or Relapsed/Refractory CLL

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
In ACE-CL-003, acalabrutinib plus venetoclax and an anti-CD20 antibody was generally well tolerated and yielded high CR/CRi and uMRD rates in both RR and TN CLL.
Format: Microsoft PowerPoint (.ppt)
File Size: 566 KB
Released: December 15, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 12, 2022 Expired: May 11, 2023

Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

Clinical Care Options (CCO): Experts John M. Burke, MD, and Peter Martin, MD, review key data in lymphomas and CLL presented at the 2021 American Society of Hematology Annual Meeting

John M. Burke, MD Peter Martin, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: May 10, 2022 Expired: May 9, 2023

Enter characteristics of your patient with myelodysplastic syndrome (MDS) into this online tool to receive treatment recommendations from 5 experts.

Rami S. Komrokji, MD
Program Director
Amy E. DeZern, MD, MHS Daniel Pollyea, MD, MS Michael J. Savona, MD Amer Zeidan, MBBS
Released: May 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings